Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bluetongue virus (BTV) is a double-stranded RNA (dsRNA) virus and the type species of the genus Orbivirus in the family Reoviridae (Mertens et al., 2005). It is the causative agent of bluetongue, a significant veterinary disease affecting ruminants, including sheep, cattle, goats, and deer, characterized by vascular damage, edema, and hemorrhage (Maclachlan et al., 2009). The virus is transmitted by hematophagous midges of the genus Culicoides, making its spread highly dependent on environmental and climatic factors (Purse et al., 2005). The BTV particle is a complex non-enveloped structure composed of three concentric protein layers surrounding a genome of ten segments (Belhouchet et al., 2011). While BTV itself is a pathogen rather than a single molecular target, its individual components, particularly the outer capsid protein VP2 and the highly conserved core protein VP7, are the primary targets for neutralizing antibodies and diagnostic detection (Huismans and van Dijk, 1990). Therapeutic intervention is currently limited to prophylactic vaccination and vector control, as there are no widely approved antiviral drugs for clinical use in affected livestock (Savini et al., 2008).
Vaccines work by inducing neutralizing antibodies, primarily against the VP2 protein, which prevents the virus from attaching to and entering host cells (Huismans and van Dijk, 1990). Experimental antiviral approaches have explored the use of RNA interference (RNAi) or small molecules like ribavirin to inhibit viral replication by targeting the viral RNA-dependent RNA polymerase (VP1) (Stassen et al., 2012).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bluetongue virus (BTV) (BTV).